Positive somatostatin receptor imaging does not predict somatostatin analogue efficacy in tumor-induced osteomalacia

Pol Arch Intern Med. 2018 Sep 28;128(9):554-555. doi: 10.20452/pamw.4318. Epub 2018 Aug 24.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antineoplastic Agents, Hormonal / therapeutic use
  • Humans
  • Male
  • Mesenchymoma / complications*
  • Mesenchymoma / diagnostic imaging
  • Mesenchymoma / drug therapy
  • Mesenchymoma / surgery
  • Neoplasms, Connective Tissue / diagnostic imaging
  • Neoplasms, Connective Tissue / drug therapy
  • Neoplasms, Connective Tissue / etiology*
  • Neoplasms, Connective Tissue / surgery
  • Octreotide / therapeutic use
  • Osteomalacia
  • Paraneoplastic Syndromes
  • Receptors, Somatostatin / analysis*
  • Somatostatin / analogs & derivatives*
  • Somatostatin / therapeutic use
  • Treatment Outcome

Substances

  • Antineoplastic Agents, Hormonal
  • Receptors, Somatostatin
  • Somatostatin
  • pasireotide
  • Octreotide

Supplementary concepts

  • Malignant mesenchymal tumor
  • Oncogenic osteomalacia